Status:
UNKNOWN
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
Lead Sponsor:
Nathan Kline Institute for Psychiatric Research
Collaborating Sponsors:
Columbia University
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
Persistent neurocognitive deficits are a major cause of severe disability and impaired long-term psychosocial outcome in schizophrenia (SZ). In particular, within the auditory system, early deficits s...
Eligibility Criteria
Inclusion
- 18 to 64 years old, IQ≥85 and estimated Glomerular Filtration Rate (GFR) \< or =60. All oral and depot antipsychotics (with the exception of clozapine) are allowable.
- Patients must be on their antipsychotic medication for 1 month and stable on dose of antipsychotic and adjunctive medications for 2 weeks prior to study entry.
Exclusion
- Include a history of neurological visual or hearing impairment, active suicidal ideation on the Calgary Depression Scale (CDS), current alcohol or drug abuse (\<1 month) or substance dependence (\<4 months).
- All women of child-bearing potential must have a negative serum pregnancy test at the baseline visit.
- We require an IQ of greater or equal to 85 to ensure that subjects will have a capacity to learn.
- In our cross-sectional studies, we have observed an IQ greater than 85 in over 90% of candidates, suggesting that this is not an overly restrictive criterion.
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01474395
Start Date
March 1 2012
End Date
June 1 2013
Last Update
October 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nathan Kline Insitute for Psychiatric Research
Orangeburg, New York, United States, 10962